CRISPR 诊断市场－全球产业规模、份额、趋势、机会和预测（按产品、技术、应用、最终用户、地区和竞争细分，2020-2030 年）

2024 年全球基于 CRISPR 的诊断市值为 31.6 亿美元，预计到 2030 年将达到 81.2 亿美元，预测期内的复合年增长率为 17.02%。由于对准确、经济高效和快速的分子诊断工具的需求不断增长，该市场正在经历快速成长。基于 CRISPR 的诊断技术利用基因编辑机制高精度检测 DNA 或 RNA 序列，有助于早期识别传染病、遗传疾病和癌症。这些工具在即时检测、个人化医疗和伴随诊断的应用日益广泛，正在加速市场采用。不断扩大的研究投资、生物技术公司与学术机构之间的合作以及向分散检测的转变进一步推动了成长。这些诊断技术只需极少的样品製备即可提供结果，并且不需要先进的实验室基础设施，非常适合临床和远端环境。

关键市场驱动因素

CRISPR技术和平台开发的进展

主要市场挑战

有限的临床验证和标准化

主要市场趋势

扩展即时护理和居家检测应用

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球基于 CRISPR 的诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 副产品（酵素、试剂盒和试剂、软体和库）
  • 按技术（Cas9、Cas12、其他）
  • 按应用（传染病诊断、遗传疾病诊断、癌症诊断、其他）
  • 按最终用户（医院和诊所诊断、实验室、製药和生物技术公司等）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美基于 CRISPR 的诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲基于 CRISPR 的诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区 CRISPR 诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美CRISPR诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲 CRISPR 诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Thermo Fisher Scientific Inc.
• Integrated DNA Technologies, Inc.
• Molbio Diagnostics
• Horizon Discovery
• Synthego Corporation
• Mammoth Biosciences
• Sherlock Biosciences
• Caribou Biosciences
• CrisprBits
• ToolGen Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

The Global CRISPR-Based Diagnostics Market was valued at USD 3.16 billion in 2024 and is projected to reach USD 8.12 billion by 2030, growing at a CAGR of 17.02% during the forecast period. This market is witnessing rapid growth due to rising demand for accurate, cost-efficient, and fast molecular diagnostic tools. CRISPR-based diagnostics utilize gene-editing mechanisms to detect DNA or RNA sequences with high precision, aiding early identification of infectious diseases, genetic conditions, and cancers. The increasing application of these tools in point-of-care testing, personalized medicine, and companion diagnostics is accelerating market adoption. Growth is further fueled by expanding research investments, collaborations between biotech firms and academic institutions, and a shift toward decentralized testing. These diagnostics offer results with minimal sample preparation and without the need for advanced lab infrastructure, making them well-suited for both clinical and remote environments.

Key Market Drivers

Advancements in CRISPR Technology and Platform Development

Technological progress in CRISPR systems and platform innovations is significantly contributing to market growth. Enhanced enzyme engineering has improved the specificity and efficiency of Cas variants like Cas12, Cas13, and Cas14, enabling detection of multiple biomarkers with reduced off-target effects. Developments in portable diagnostic formats-such as lateral-flow strips, paper-based assays, and microfluidic devices-have made CRISPR tools accessible and easy to use, even outside of laboratory settings. Integration with AI for guide RNA design and interpretation software has improved diagnostic accuracy and user experience. Public-sector initiatives are also fostering innovation; for example, the NIH's Somatic Cell Genome Editing (SCGE) Program allocated USD 89 million in 2024 to improve genome-editing technologies, while a USD 27 million project launched a Genomics Learning Health System Network to incorporate genomic diagnostics into routine care.

Key Market Challenges

Limited Clinical Validation and Standardization

Despite promising laboratory results, CRISPR-based diagnostics face hurdles due to limited clinical validation and lack of standardization. Large-scale, peer-reviewed clinical trials evaluating these technologies across diverse populations and biological sample types are still sparse. Many current assays lack proven efficacy in complex samples such as blood or saliva, where potential interferences can compromise accuracy. This insufficient validation presents challenges for regulatory approvals and delays adoption in clinical settings. Medical institutions require comprehensive, reproducible evidence to trust and implement new diagnostic platforms, and the current data gaps hinder wider integration into healthcare systems.

Key Market Trends

Expansion of Point-of-Care and At-Home Testing Applications

The move toward decentralized diagnostic solutions is shaping the growth trajectory of CRISPR-based diagnostics. Traditional lab-based diagnostics can be slow and require skilled personnel, but CRISPR platforms offer a quicker, simpler alternative. Innovations in lyophilized reagents, compact lateral flow systems, and microfluidic devices have paved the way for CRISPR-based tests suitable for primary care, pharmacies, and even home use. These solutions are particularly valuable in low-resource or rural settings. Growing interest in remote healthcare and instant diagnostic results-especially for infectious diseases, chronic conditions, and genetic screening-is fueling demand. Additionally, smartphone-compatible, user-operated devices are gaining popularity among consumers. Features such as disposable cartridges, refrigeration-free storage, and minimal training requirements are making CRISPR diagnostics increasingly viable for widespread, non-laboratory applications.

Key Market Players

• Thermo Fisher Scientific Inc.
• Integrated DNA Technologies, Inc.
• Molbio Diagnostics
• Horizon Discovery
• Synthego Corporation
• Mammoth Biosciences
• Sherlock Biosciences
• Caribou Biosciences
• CrisprBits
• ToolGen Inc.

Report Scope:

In this report, the Global CRISPR-Based Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CRISPR-Based Diagnostics Market, By Product:

• Enzymes
• Kits and Reagents
• Software and Libraries

CRISPR-Based Diagnostics Market, By Technology:

• Cas9
• Cas12
• Others

CRISPR-Based Diagnostics Market, By Application:

• Infectious Disease Diagnostics
• Genetic Disorder Diagnostics
• Cancer Diagnostics
• Others

CRISPR-Based Diagnostics Market, By End User:

• Hospitals and Clinics Diagnostic
• Laboratories
• Pharmaceutical and Biotechnology Companies
• Others

CRISPR-Based Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CRISPR-Based Diagnostics Market.

Available Customizations:

Global CRISPR-Based Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global CRISPR-Based Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Enzymes, Kits and Reagents, Software and Libraries)
  • 5.2.2. By Technology (Cas9, Cas12, Others)
  • 5.2.3. By Application (Infectious Disease Diagnostics, Genetic Disorder Diagnostics, Cancer Diagnostics, Others)
  • 5.2.4. By End User (Hospitals and Clinics Diagnostic, Laboratories, Pharmaceutical and Biotechnology Companies, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America CRISPR-Based Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States CRISPR-Based Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico CRISPR-Based Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada CRISPR-Based Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe CRISPR-Based Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France CRISPR-Based Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany CRISPR-Based Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom CRISPR-Based Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy CRISPR-Based Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain CRISPR-Based Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific CRISPR-Based Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China CRISPR-Based Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India CRISPR-Based Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea CRISPR-Based Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan CRISPR-Based Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia CRISPR-Based Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America CRISPR-Based Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil CRISPR-Based Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina CRISPR-Based Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia CRISPR-Based Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa CRISPR-Based Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa CRISPR-Based Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia CRISPR-Based Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE CRISPR-Based Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Integrated DNA Technologies, Inc.
• 15.3. Molbio Diagnostics
• 15.4. Horizon Discovery
• 15.5. Synthego Corporation
• 15.6. Mammoth Biosciences
• 15.7. Sherlock Biosciences
• 15.8. Caribou Biosciences
• 15.9. CrisprBits
• 15.10. ToolGen Inc.

16. Strategic Recommendations

17. About Us & Disclaimer